Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DZD1516 |
Trade Name | |
Synonyms | DZD-1516|DZD 1516 |
Drug Descriptions |
DZD1516 is an ERBB2 (HER2) inhibitor that penetrates the blood brain barrier, and upon binding to ERRB2 (HER2), prevents ERBB2 (HER2)-dependent signaling, potentially leading to tumor cell death (NCI Drug Dictionary). |
DrugClasses | HER2 Inhibitor 42 |
CAS Registry Number | NA |
NCIT ID | C174039 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ado-trastuzumab emtansine + DZD1516 | Ado-trastuzumab emtansine DZD1516 | 0 | 1 |
Capecitabine + DZD1516 | Capecitabine DZD1516 | 0 | 1 |
Capecitabine + DZD1516 + Trastuzumab | Capecitabine DZD1516 Trastuzumab | 0 | 1 |
DZD1516 | DZD1516 | 0 | 1 |
DZD1516 + Trastuzumab | DZD1516 Trastuzumab | 0 | 1 |